Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.770
+0.010 (0.27%)
At close: Apr 28, 2026, 4:00 PM EDT
3.840
+0.070 (1.86%)
After-hours: Apr 28, 2026, 6:40 PM EDT
Voyager Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 40.37 | 80 | 250.01 | 40.91 | 37.42 | |
| Revenue Growth (YoY) | -49.53% | -68.00% | 511.16% | 9.33% | -78.14% | |
| Cost of Revenue | 132.27 | 124.59 | 92.17 | 55.76 | 73.79 | |
| Gross Profit | -91.9 | -44.59 | 157.84 | -14.86 | -36.37 | |
| Selling, General & Admin | 36.44 | 35.92 | 35.82 | 30.98 | 37.25 | |
| Operating Expenses | 36.44 | 35.92 | 35.82 | 30.98 | 37.25 | |
| Operating Income | -128.34 | -80.51 | 122.01 | -45.84 | -73.62 | |
| Interest Expense | - | - | - | - | -0.39 | |
| Interest & Investment Income | 10.62 | 18.33 | 11.72 | 1.79 | - | |
| Other Non Operating Income (Expenses) | 1.65 | 0.62 | 0 | 2.65 | - | |
| EBT Excluding Unusual Items | -116.08 | -61.56 | 133.74 | -41.39 | -74.01 | |
| Merger & Restructuring Charges | -3.5 | - | - | - | - | |
| Gain (Loss) on Sale of Investments | - | - | - | - | 2.81 | |
| Asset Writedown | - | -2.78 | - | - | - | |
| Other Unusual Items | - | - | - | -5 | - | |
| Pretax Income | -119.58 | -64.34 | 133.74 | -46.39 | -71.2 | |
| Income Tax Expense | 0.14 | 0.67 | 1.41 | 0.02 | - | |
| Net Income | -119.72 | -65 | 132.33 | -46.41 | -71.2 | |
| Net Income to Common | -119.72 | -65 | 132.33 | -46.41 | -71.2 | |
| Shares Outstanding (Basic) | 59 | 58 | 43 | 38 | 38 | |
| Shares Outstanding (Diluted) | 59 | 58 | 45 | 38 | 38 | |
| Shares Change (YoY) | 1.77% | 29.39% | 16.20% | 1.83% | 0.86% | |
| EPS (Basic) | -2.04 | -1.13 | 3.08 | -1.21 | -1.89 | |
| EPS (Diluted) | -2.04 | -1.13 | 2.97 | -1.21 | -1.89 | |
| Free Cash Flow | -135.06 | -18.83 | 74.66 | -15 | -55.13 | |
| Free Cash Flow Per Share | -2.30 | -0.33 | 1.68 | -0.39 | -1.46 | |
| Gross Margin | -227.62% | -55.74% | 63.13% | -36.32% | -97.21% | |
| Operating Margin | -317.89% | -100.64% | 48.80% | -112.05% | -196.76% | |
| Profit Margin | -296.53% | -81.25% | 52.93% | -113.45% | -190.29% | |
| Free Cash Flow Margin | -334.53% | -23.54% | 29.86% | -36.67% | -147.36% | |
| EBITDA | -124.28 | -75.78 | 126.46 | -39.65 | -68.45 | |
| EBITDA Margin | - | -94.72% | 50.58% | -96.92% | -182.96% | |
| D&A For EBITDA | 4.06 | 4.73 | 4.44 | 6.19 | 5.17 | |
| EBIT | -128.34 | -80.51 | 122.01 | -45.84 | -73.62 | |
| EBIT Margin | - | -100.64% | 48.80% | -112.05% | -196.76% | |
| Effective Tax Rate | - | - | 1.05% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.